scholarly journals Comparison of gentamicin distribution in the inner ear following administration via the endolymphatic sac or round window

2010 ◽  
Vol 120 (10) ◽  
pp. 2054-2060 ◽  
Author(s):  
Yiliang Zhang ◽  
Ru Zhang ◽  
Chunfu Dai ◽  
Peter S. Steyger ◽  
Yongfu Yu
1987 ◽  
Vol 103 (5) ◽  
pp. 182-188 ◽  
Author(s):  
Shunichi Tomiyama ◽  
Jeffrey Harris
Keyword(s):  

2000 ◽  
Vol 59 (1) ◽  
pp. 45-51
Author(s):  
Tatsuya Yamasoba ◽  
Masao Yagi ◽  
Mitsuya Suzuki

ORL ◽  
1990 ◽  
Vol 52 (3) ◽  
pp. 143-148 ◽  
Author(s):  
Hans Jörg Altermatt ◽  
Jan-Olaf Gebbers ◽  
Christoph Müller ◽  
Wolfgang Arnold ◽  
Jean Albert Laissue

2015 ◽  
Vol 2015 ◽  
pp. 1-6 ◽  
Author(s):  
Daniele Bernardeschi ◽  
Yann Nguyen ◽  
Francesca Yoshie Russo ◽  
Isabelle Mosnier ◽  
Evelyne Ferrary ◽  
...  

Objective. To evaluate the cutaneous and the inner ear tolerance of bioactive glass S53P4 when used in the mastoid and epitympanic obliteration for chronic otitis surgery.Material and Methods. Forty-one cases have been included in this prospective study. Cutaneous tolerance was clinically evaluated 1 week, 1 month, and 3 months after surgery with a physical examination of the retroauricular and external auditory canal (EAC) skin and the presence of otalgia; the inner ear tolerance was assessed by bone-conduction hearing threshold 1 day after surgery and by the presence of vertigo or imbalance.Results. All surgeries but 1 were uneventful: all patients maintained the preoperative bone-conduction hearing threshold except for one case in which the round window membrane was opened during the dissection of the cholesteatoma in the hypotympanum and this led to a dead ear. No dizziness or vertigo was reported. Three months after surgery, healing was achieved in all cases with a healthy painless skin. No cases of revision surgery for removal of the granules occurred in this study.Conclusion. The bioactive glass S53P4 is a well-tolerated biomaterial for primary or revision chronic otitis surgery, as shown by the local skin reaction which lasted less than 3 months and by the absence of labyrinthine complications.


1980 ◽  
Vol 89 (3_suppl) ◽  
pp. 249-253 ◽  
Author(s):  
Michael M. Paparella ◽  
Marcos V. Goycoolea ◽  
William L. Meyerhoff

Insidious inner ear complications of otitis media have been and are being studied in our laboratory. The purpose of this paper is to review these studies, coordinate, capsulize and highlight the results with emphasis on the transport role of the round window membrane.


1987 ◽  
Vol 103 (3-4) ◽  
pp. 182-188 ◽  
Author(s):  
Shunichi Tomiyama ◽  
Jeffrey P. Harris
Keyword(s):  

1997 ◽  
Vol 830 (1 Immunologic D) ◽  
pp. 243-252 ◽  
Author(s):  
M. BARBARA ◽  
G. ATTANASIO ◽  
V. PETROZZA ◽  
A. MODESTI ◽  
R. FILIPO

2016 ◽  
Vol 230 (2) ◽  
pp. 297-302 ◽  
Author(s):  
Martin N. Møller ◽  
Svend Kirkeby ◽  
Per Cayé-Thomasen

Author(s):  
Rogan Corbridge ◽  
Nicholas Steventon

Drugs used in the ear 348 Drugs used in the nose 349 Drugs used in the treatment of acid reflux 350 This group of drugs is widely used for the treatment of otitis externa. Otitis externa 2 drops tds for 10 days Presence of grommet or tympanic membrane perforation due to aminoglycoside ototoxicity in the inner ear. Risk thought to be low in the presence of active infection where the middle-ear mucosa is swollen and the antibiotic is unlikely to reach the inner ear via the round window...


Sign in / Sign up

Export Citation Format

Share Document